JP2012201599A5 - - Google Patents

Download PDF

Info

Publication number
JP2012201599A5
JP2012201599A5 JP2011064911A JP2011064911A JP2012201599A5 JP 2012201599 A5 JP2012201599 A5 JP 2012201599A5 JP 2011064911 A JP2011064911 A JP 2011064911A JP 2011064911 A JP2011064911 A JP 2011064911A JP 2012201599 A5 JP2012201599 A5 JP 2012201599A5
Authority
JP
Japan
Prior art keywords
propionic acid
blood cholesterol
cholesterol
reducing agent
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011064911A
Other languages
Japanese (ja)
Other versions
JP2012201599A (en
JP5818309B2 (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2011064911A priority Critical patent/JP5818309B2/en
Priority claimed from JP2011064911A external-priority patent/JP5818309B2/en
Publication of JP2012201599A publication Critical patent/JP2012201599A/en
Publication of JP2012201599A5 publication Critical patent/JP2012201599A5/ja
Application granted granted Critical
Publication of JP5818309B2 publication Critical patent/JP5818309B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (11)

プロピオン酸菌の菌体を有効成分として含む血中コレステロール低減剤。   A blood cholesterol-reducing agent containing cells of propionic acid bacteria as an active ingredient. プロピオン酸菌の菌体が死菌体である、請求項1に記載の血中コレステロール低減剤。   The blood cholesterol reducing agent according to claim 1, wherein the cells of propionic acid bacteria are dead cells. プロピオン酸菌がPropionibacterium freudenreichii ET-3株(受託番号FERM BP-8115)、Propionibacterium acidipropionici JCM6427株、及びPropionibacterium jensenii JCM6433株からなる群のうち1つ又は複数である、請求項1又は2に記載の血中コレステロール低減剤。   The blood according to claim 1 or 2, wherein the propionic acid bacterium is one or more of the group consisting of Propionibacterium freudenreichii ET-3 strain (Accession No. FERM BP-8115), Propionibacterium acidipropionici JCM6427 strain, and Propionibacterium jensenii JCM6433 strain. Medium cholesterol reducing agent. プロピオン酸菌の菌体が、洗浄及び滅菌処理されている、請求項1〜3のいずれか1項に記載の血中コレステロール低減剤。   The blood cholesterol-reducing agent according to any one of claims 1 to 3, wherein the cells of propionic acid bacteria are washed and sterilized. 血中コレステロールの低減が、血清総コレステロールの低減を含む、請求項1〜4のいずれか1項に記載の血中コレステロール低減剤。The blood cholesterol reducing agent according to any one of claims 1 to 4, wherein the reduction of blood cholesterol includes reduction of serum total cholesterol. 血中コレステロールの低減が、血清VLDL-コレステロールとLDL-コレステロールの総和の低減を含む、請求項1〜5のいずれか1項に記載の血中コレステロール低減剤。The blood cholesterol reducing agent according to any one of claims 1 to 5, wherein the reduction of blood cholesterol comprises reduction of the sum of serum VLDL-cholesterol and LDL-cholesterol. 請求項1〜のいずれか1項記載の血中コレステロール低減剤と製剤補助剤とを含む、血中コレステロール低減のための組成物。 A composition for reducing blood cholesterol, comprising the blood cholesterol reducing agent according to any one of claims 1 to 6 and a formulation adjuvant. プロピオン酸菌の菌体と製剤補助剤とを含む血中コレステロール低減のための飲食品。   A food and drink for reducing blood cholesterol, which comprises cells of propionic acid bacteria and a preparation auxiliary agent. プロピオン酸菌が死菌体である、請求項に記載の飲食品。 The food or drink according to claim 8 , wherein the propionic acid bacterium is a dead cell. プロピオン酸菌がPropionibacterium freudenreichii ET-3(受託番号FERM BP-8115)、Propionibacterium acidipropionici JCM6427、及びPropionibacterium jensenii JCM6433からなる群のうち1つ又は複数である、請求項又はに記載の飲食品。 The food or drink according to claim 8 or 9 , wherein the propionic acid bacterium is one or more of the group consisting of Propionibacterium freudenreichii ET-3 (Accession No. FERM BP-8115), Propionibacterium acidipropionici JCM6427, and Propionibacterium jensenii JCM6433. プロピオン酸菌の菌体が、洗浄及び滅菌処理されている、請求項10のいずれか1項に記載の飲食品。 Cells of propionic acid bacterium, are cleaned and sterilized, food and drink according to any one of claims 8-10.
JP2011064911A 2011-03-23 2011-03-23 Blood cholesterol reducing agent Active JP5818309B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011064911A JP5818309B2 (en) 2011-03-23 2011-03-23 Blood cholesterol reducing agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011064911A JP5818309B2 (en) 2011-03-23 2011-03-23 Blood cholesterol reducing agent

Publications (3)

Publication Number Publication Date
JP2012201599A JP2012201599A (en) 2012-10-22
JP2012201599A5 true JP2012201599A5 (en) 2014-04-03
JP5818309B2 JP5818309B2 (en) 2015-11-18

Family

ID=47182952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011064911A Active JP5818309B2 (en) 2011-03-23 2011-03-23 Blood cholesterol reducing agent

Country Status (1)

Country Link
JP (1) JP5818309B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102154124B1 (en) * 2019-06-14 2020-09-09 고려대학교 산학협력단 A composition for preventing, treating, or improving metabolic syndrome and obesity-related metabolic syndrome comprising the Propionibacterium freudenreichii MJ2 strain as an active ingredient
JP7402628B2 (en) * 2019-07-19 2023-12-21 株式会社明治 Composition
JP7402629B2 (en) * 2019-07-19 2023-12-21 国立大学法人東京農工大学 Composition containing propionic acid bacteria fermented product

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537242A (en) * 2002-06-21 2008-10-31 Newcastle Innovation Ltd Probiotic propionibacterium jensenii 702
KR20100087078A (en) * 2007-11-27 2010-08-03 메이지뉴교오가부시기가이샤 Agent and method for improving survivability of lactic acid bacterium, and food composition

Similar Documents

Publication Publication Date Title
Chee et al. Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health
JP7387587B2 (en) Novel uses in the treatment of Clostridium difficile infections
RU2664479C2 (en) Compositions and methods
Nueno-Palop et al. Probiotic assessment of Enterococcus faecalis CP58 isolated from human gut
Angelakis et al. Related actions of probiotics and antibiotics on gut microbiota and weight modification
Neville et al. Probiotic properties of Lactobacillus salivarius and closely related Lactobacillus species
Waldman et al. The human microbiota, infectious disease, and global health: challenges and opportunities
Ng et al. Evaluation of probiotic potential of lactic acid bacteria isolated from traditional Malaysian fermented Bambangan (Mangifera pajang)
JP2016537410A5 (en)
PH12014501254A1 (en) Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof
JP2008538288A5 (en)
RU2018106510A (en) The composition of lactic acid bacteria for use in the treatment of infections caused by Propionibacterium acnes, and, in particular, acne
RU2013153578A (en) POLYBACTERIAL DRUG WITH ADVANTAGES FOR HEALTH: WITH ANTIOXIDANT EFFECT, REDUCED CONCENTRATION OF CHOLESTEROL, ANTI-INFLAMMATIVE EFFECT AND SUSTAINABILITY
WO2012091081A8 (en) Interferon production-inducing agent containing lactic acid bacteria
Watanabe et al. Prebiotic properties of epilactose
WO2009013709A3 (en) Zinc-enriched biomass, method for the preparation thereof and pro-biotic, cosmetic, dietary and nutraceutic products comprising the same
RU2013148473A (en) BACTERIAL STRAINS ABLE TO METABOLIZE OXALATES
JP2011504366A5 (en)
WO2009066537A1 (en) Immunoregulatory function inducer and food composition
JP2015525572A5 (en)
JP2012201599A5 (en)
Lindström et al. Oral administration of live exopolysaccharide-producing Pediococcus parvulus, but not purified exopolysaccharide, suppressed Enterobacteriaceae without affecting bacterial diversity in ceca of mice
Xiong et al. Titer dynamic analysis of D29 within MTB-infected macrophages and effect on immune function of macrophages
Del Piano et al. Assessment of the capability of a gelling complex made of tara gum and the exopolysaccharides produced by the microorganism Streptococcus thermophilus ST10 to prospectively restore the gut physiological barrier: a pilot study
JP2009232702A5 (en)